|
MX359371B
(es)
|
2001-11-13 |
2018-09-25 |
Univ Pennsylvania |
Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
EP2345731B1
(en)
|
2003-09-30 |
2015-10-21 |
The Trustees of the University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
|
ES2535877T3
(es)
*
|
2006-06-19 |
2015-05-18 |
Asklepios Biopharmaceutical, Inc. |
Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
ES2714007T3
(es)
|
2007-04-09 |
2019-05-24 |
Univ Florida |
Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
|
|
WO2010011404A2
(en)
|
2008-05-20 |
2010-01-28 |
Eos Neuroscience, Inc. |
Vectors for delivery of light-sensitive proteins and methods of use
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
EP2425000B1
(en)
*
|
2009-04-30 |
2019-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2011038187A1
(en)
|
2009-09-25 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP2605798A1
(en)
|
2010-07-12 |
2013-06-26 |
Universidad Autònoma de Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
WO2012057363A1
(ja)
*
|
2010-10-27 |
2012-05-03 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
EP3318635A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
CN105755044A
(zh)
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
MX367100B
(es)
*
|
2012-02-17 |
2019-08-05 |
The Children´S Hospital Of Philadelphia |
Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
|
|
NZ701693A
(en)
|
2012-04-18 |
2017-02-24 |
The Children’S Hospital Of Philadelphia |
Composition and methods for highly efficient gene transfer using aav capsid variants
|
|
TWI698240B
(zh)
|
2012-05-15 |
2020-07-11 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
AU2013296425B2
(en)
|
2012-08-01 |
2018-06-07 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
EP2900686B1
(en)
*
|
2012-09-28 |
2020-06-10 |
The University of North Carolina At Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
|
AU2014235096B2
(en)
|
2013-03-15 |
2020-03-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating MPSI
|
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
|
EP3492597A3
(en)
*
|
2013-05-21 |
2019-08-28 |
University of Florida Research Foundation, Inc. |
Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
|
|
EP3003391B1
(en)
*
|
2013-05-31 |
2021-09-22 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
IL297919A
(en)
|
2013-07-22 |
2023-01-01 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
WO2015048534A1
(en)
|
2013-09-26 |
2015-04-02 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
CN106029107A
(zh)
*
|
2013-10-07 |
2016-10-12 |
基罗米克有限责任公司 |
使用疾病特异性启动子治疗心血管疾病的组合物和方法
|
|
CN106232618A
(zh)
*
|
2013-10-11 |
2016-12-14 |
马萨诸塞眼科耳科诊所 |
预测祖先病毒序列的方法及其用途
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
SMT202000531T1
(it)
|
2014-03-09 |
2020-11-10 |
Univ Pennsylvania |
Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc)
|
|
EP3800191B1
(en)
|
2014-03-17 |
2025-08-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
CA2942515C
(en)
|
2014-03-18 |
2025-12-09 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
EP3134431B1
(en)
|
2014-04-25 |
2021-04-07 |
The Trustees Of The University Of Pennsylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
LT3137497T
(lt)
|
2014-05-02 |
2021-07-26 |
Genzyme Corporation |
Aav vektoriai, skirti tinklainės ir cns genų terapijai
|
|
ES2833230T3
(es)
|
2014-05-13 |
2021-06-14 |
Univ Pennsylvania |
Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
CN107427557B
(zh)
*
|
2014-08-13 |
2022-01-04 |
费城儿童医院 |
用于包装和表达变体因子viii以治疗血友病的改良表达组件
|
|
EP3194430A1
(en)
|
2014-09-16 |
2017-07-26 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP4344741A3
(en)
|
2014-11-21 |
2024-08-28 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
US11033638B2
(en)
|
2015-01-07 |
2021-06-15 |
Universität Autonoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11021519B2
(en)
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
KR20240119152A
(ko)
|
2015-03-10 |
2024-08-06 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
재조합 glut1 아데노-관련 바이러스 벡터 작제물 및 glut1 발현을 회복하기 위한 관련된 방법
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
US10555994B2
(en)
*
|
2015-03-30 |
2020-02-11 |
Boehringer Ingelheim Animal Health USA Inc. |
PCV2 ORF2 carrier platform
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
EP3291765A4
(en)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
METHOD FOR THE DELIVERY OF AN ACTIVE SUBSTANCE TO THE EYE
|
|
EA201792500A1
(ru)
|
2015-05-13 |
2018-04-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Aav-опосредованная экспрессия антител против гриппа и способы их использования
|
|
MX390848B
(es)
|
2015-06-23 |
2025-03-21 |
Childrens Hospital Philadelphia |
Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
|
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
CN108603235A
(zh)
|
2015-07-30 |
2018-09-28 |
马萨诸塞眼科耳科诊所 |
祖先病毒序列及其用途
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
|
WO2017035416A2
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
|
CA2995733A1
(en)
|
2015-08-31 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Aav-epo for treating companion animals
|
|
CN108291216B
(zh)
|
2015-09-24 |
2022-09-16 |
宾夕法尼亚州大学信托人 |
用于治疗补体介导的疾病的组合物和方法
|
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US12188037B2
(en)
*
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
CN108779167A
(zh)
|
2015-10-28 |
2018-11-09 |
宾夕法尼亚州大学信托人 |
鞘内施用腺伴随病毒载体用于基因治疗
|
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3384035A4
(en)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
|
|
AU2016366560A1
(en)
|
2015-12-11 |
2018-06-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
SG10201913266UA
(en)
|
2015-12-11 |
2020-02-27 |
Massachusetts Eye & Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
US11028372B2
(en)
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
|
CA3008264A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
JP7406783B2
(ja)
|
2015-12-14 |
2023-12-28 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
|
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012195A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
SG10201912761UA
(en)
|
2016-04-15 |
2020-02-27 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
SG11201808812RA
(en)
*
|
2016-04-15 |
2018-11-29 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
|
SG11201808426XA
(en)
|
2016-04-15 |
2018-10-30 |
Univ Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11364308B2
(en)
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
CN109415730A
(zh)
|
2016-06-13 |
2019-03-01 |
北卡罗来纳大学教堂山分校 |
优化的cln1基因和表达盒以及它们的应用
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
WO2018009814A1
(en)
|
2016-07-08 |
2018-01-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
IL305149A
(en)
*
|
2016-07-26 |
2023-10-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
AU2017302013B2
(en)
|
2016-07-29 |
2022-05-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
IL315358A
(en)
|
2016-08-18 |
2024-11-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
EP3575398A4
(en)
*
|
2017-01-30 |
2020-11-11 |
Nippon Medical School Foundation |
ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
EP3585883A4
(en)
|
2017-02-21 |
2021-04-14 |
University of Florida Research Foundation, Incorporated |
MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
|
|
PT3589730T
(pt)
|
2017-02-28 |
2024-02-28 |
Univ Pennsylvania |
Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
|
|
UY37620A
(es)
|
2017-02-28 |
2018-08-31 |
Univ Pennsylvania |
Vacunas contra la gripe mediadas por aav novedosas
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
RU2019130004A
(ru)
|
2017-03-01 |
2021-04-01 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия при глазных заболеваниях
|
|
CA3055200A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
KR102746901B1
(ko)
|
2017-03-03 |
2024-12-26 |
옵시디안 테라퓨틱스, 인크. |
Cd19 조성물 및 면역요법을 위한 방법
|
|
KR20190139951A
(ko)
|
2017-04-14 |
2019-12-18 |
리젠엑스바이오 인크. |
인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
|
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
CN108103082B
(zh)
*
|
2017-05-11 |
2021-07-13 |
北京锦篮基因科技有限公司 |
一种腺相关病毒介导的lcat基因表达载体及其用途
|
|
IL316926A
(en)
|
2017-05-11 |
2025-01-01 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinosis
|
|
IL270882B2
(en)
|
2017-05-24 |
2024-02-01 |
Univ Barcelona Autonoma |
Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21
|
|
EP3630986B1
(en)
|
2017-05-31 |
2026-03-25 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
JP7766393B2
(ja)
|
2017-06-14 |
2025-11-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3053154A1
(en)
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
AU2018320849A1
(en)
*
|
2017-08-25 |
2020-03-05 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
KR102883778B1
(ko)
|
2017-09-22 |
2025-11-12 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
MX2020003888A
(es)
|
2017-10-18 |
2020-11-06 |
Regenxbio Inc |
Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
|
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
AU2018375164B2
(en)
|
2017-11-30 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for Mucopolysaccharidosis IIIA
|
|
CN111989396A
(zh)
|
2017-11-30 |
2020-11-24 |
宾夕法尼亚州大学信托人 |
用于iiib型粘多糖贮积病的基因疗法
|
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
|
|
US10806802B2
(en)
|
2018-01-18 |
2020-10-20 |
University Of Guelph |
Adeno-associated virus particle with mutated capsid and methods of use thereof
|
|
US12305185B2
(en)
|
2018-01-23 |
2025-05-20 |
Mount Spec Investments Pty Ltd |
Expression vector and method
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
IL276859B2
(en)
*
|
2018-02-27 |
2025-12-01 |
Univ Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
|
EP3768695A4
(en)
*
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
|
JP2021519612A
(ja)
*
|
2018-03-29 |
2021-08-12 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
中和を回避する肝臓向性組換えａａｖ６ベクター
|
|
MA51353B1
(fr)
|
2018-04-05 |
2022-09-30 |
Univ Sorbonne |
Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
|
|
US12037707B2
(en)
|
2018-04-05 |
2024-07-16 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation
|
|
US12460226B2
(en)
|
2018-04-16 |
2025-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
CN112312929A
(zh)
|
2018-04-18 |
2021-02-02 |
纽约市哥伦比亚大学理事会 |
用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
WO2019212922A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
AU2019265663B2
(en)
|
2018-05-08 |
2024-06-13 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
EP3823981A4
(en)
|
2018-07-17 |
2022-04-06 |
Neuromyon Inc. |
TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
|
|
CN112770812A
(zh)
|
2018-07-24 |
2021-05-07 |
沃雅戈治疗公司 |
产生基因治疗制剂的系统和方法
|
|
KR20210052450A
(ko)
*
|
2018-07-31 |
2021-05-10 |
코넬 유니버시티 |
기관 기능을 제어하기 위한 유전자 요법 방법
|
|
EP3833745A1
(en)
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
WO2020041498A1
(en)
*
|
2018-08-21 |
2020-02-27 |
Massachusetts Eye And Ear Infirmary |
Compositions and methods for modulating transduction efficiency of adeno-associated viruses
|
|
JP7450945B2
(ja)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス， インコーポレイテッド |
ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
BR112021006052A2
(pt)
|
2018-10-01 |
2021-09-08 |
Ultragenyx Pharmaceutical Inc. |
Terapia gênica para tratar acidemia propiônica
|
|
CA3114175A1
(en)
|
2018-10-01 |
2020-04-09 |
The Trustees Of The University Of Pennsylvania |
Beta-galactosidase based aav for treating gm1 gangliosidosis
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112912518A
(zh)
|
2018-10-15 |
2021-06-04 |
再生生物股份有限公司 |
用于测量复制缺陷型病毒载体和病毒的感染性的方法
|
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
KR20220022107A
(ko)
|
2018-12-05 |
2022-02-24 |
아베오나 테라퓨틱스 인코퍼레이티드 |
유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
|
|
DK3906066T5
(da)
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
EP3914229A4
(en)
*
|
2019-01-23 |
2022-11-02 |
University of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
WO2020160508A1
(en)
|
2019-01-31 |
2020-08-06 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
|
BR112021015817A2
(pt)
|
2019-02-22 |
2021-10-13 |
The Trustees Of The University Of Pennsylvania |
Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
EP3931337A1
(en)
|
2019-02-26 |
2022-01-05 |
The Trustees of The University of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
CN113795279B
(zh)
|
2019-03-04 |
2024-12-31 |
宾夕法尼亚州大学信托人 |
靶向akt通路的神经保护性基因疗法
|
|
EP3947700A4
(en)
|
2019-04-01 |
2023-01-04 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2020206098A1
(en)
|
2019-04-03 |
2020-10-08 |
Regenxbio Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
FI3953483T3
(fi)
|
2019-04-11 |
2023-11-30 |
Regenxbio Inc |
Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
|
|
TW202332458A
(zh)
|
2019-04-19 |
2023-08-16 |
美商銳進科斯生物股份有限公司 |
腺相關病毒載體調配物及方法
|
|
CN114127088B
(zh)
*
|
2019-04-23 |
2024-05-14 |
国家医疗保健研究所 |
变体衣壳蛋白和腺相关病毒aav变体及其药物组合物
|
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
EP3752524A4
(en)
*
|
2019-04-27 |
2021-11-24 |
Ocugen, Inc. |
ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASE
|
|
SG11202111375RA
(en)
*
|
2019-04-29 |
2021-11-29 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same
|
|
KR20220020261A
(ko)
|
2019-05-03 |
2022-02-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이염성 백질이영양증의 치료에 유용한 조성물
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
ES2948620T3
(es)
|
2019-07-10 |
2023-09-14 |
Masonic Medical Res Laboratory |
Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
|
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
MX2022000551A
(es)
*
|
2019-07-15 |
2022-05-18 |
Meiragtx Uk Ii Ltd |
Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica.
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
CN114502197A
(zh)
|
2019-08-26 |
2022-05-13 |
再生生物股份有限公司 |
用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
AU2020346062A1
(en)
|
2019-09-13 |
2022-03-24 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
WO2021071835A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
CN118221785A
(zh)
*
|
2019-10-16 |
2024-06-21 |
上海药明康德新药开发有限公司 |
新的aav变体
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
TWI908746B
(zh)
|
2019-11-28 |
2025-12-21 |
美商銳進科斯生物股份有限公司 |
微小肌縮蛋白基因療法之構築體及其用途
|
|
IL293658A
(en)
*
|
2019-12-10 |
2022-08-01 |
Homology Medicines Inc |
Adeno-associated virus preparations and a method of using them
|
|
AU2020401116A1
(en)
|
2019-12-10 |
2022-07-21 |
Takeda Pharmaceutical Company Limited |
Adeno associated virus vectors for the treatment of Hunter disease
|
|
CA3162020A1
(en)
|
2019-12-19 |
2021-06-24 |
James M. Wilson |
Compositions for treating friedreich's ataxia
|
|
WO2021138559A1
(en)
|
2019-12-31 |
2021-07-08 |
Swanbio Therapeutics Limited |
Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
KR20220131522A
(ko)
|
2020-01-22 |
2022-09-28 |
리젠엑스바이오 인크. |
완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
|
|
WO2023172491A1
(en)
|
2022-03-07 |
2023-09-14 |
Ultragenyx Pharmaceutical Inc. |
Modified batch aav production systems and methods
|
|
BR112022015183A2
(pt)
|
2020-01-29 |
2022-12-20 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
|
CA3168251A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
|
KR20220145838A
(ko)
|
2020-02-02 |
2022-10-31 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Gm1 강글리오사이드증을 치료하는 데 유용한 조성물
|
|
JP2023514204A
(ja)
|
2020-02-14 |
2023-04-05 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
|
|
BR112022016965A2
(pt)
*
|
2020-02-25 |
2022-12-06 |
Childrens Medical Res Institute |
Polipeptídeos e vetores de capsídeo do vírus adenoassociado
|
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
IL296732A
(en)
|
2020-03-27 |
2022-11-01 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
US20230242940A1
(en)
*
|
2020-04-13 |
2023-08-03 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using a vaccine against coronavirus
|
|
JP7713956B2
(ja)
|
2020-04-15 |
2025-07-28 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
MX2022014258A
(es)
|
2020-05-12 |
2023-02-22 |
Univ Pennsylvania |
Composiciones para la reducción específica de un fármaco de la expresión de transgén.
|
|
CA3177924A1
(en)
|
2020-05-12 |
2021-11-18 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
WO2021231538A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
IL298128A
(en)
|
2020-05-13 |
2023-01-01 |
Akouos Inc |
Compositions and methods for treating slc26a4-associated hearing loss
|
|
CN116390934A
(zh)
|
2020-05-26 |
2023-07-04 |
塑造治疗公司 |
功能性aav衣壳的高通量工程化
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
AU2021292200A1
(en)
|
2020-06-17 |
2023-02-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
CA3187635A1
(en)
*
|
2020-07-03 |
2022-01-06 |
Genethon |
Method for engineering novel hybrid aav capsids through hypervariable regions swapping
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
IL299762A
(en)
|
2020-07-13 |
2023-03-01 |
Univ Pennsylvania |
Useful preparations for the treatment of Charcot-Marietot disease
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
CN111876432B
(zh)
*
|
2020-07-29 |
2022-10-28 |
舒泰神（北京）生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
US12054738B2
(en)
|
2020-07-30 |
2024-08-06 |
Shape Therapeutics Inc. |
Stable cell lines for inducible production of rAAV virions
|
|
CA3190399A1
(en)
|
2020-08-24 |
2022-03-03 |
James M. Wilson |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
EP4204014A1
(en)
|
2020-08-26 |
2023-07-05 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
MX2023003699A
(es)
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
|
CA3198372A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
AU2021358781A1
(en)
|
2020-10-07 |
2023-05-18 |
Tern Therapeutics, Llc |
Gene therapy for ocular manifestations of cln2 disease
|
|
KR20230106598A
(ko)
|
2020-10-07 |
2023-07-13 |
리젠엑스바이오 인크. |
겔 제형과 같은 맥락막위 투여용 제형
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
BR112023006305A2
(pt)
|
2020-10-09 |
2023-05-09 |
Tenaya Therapeutics Inc |
Métodos e composições de terapia gênica com placofilina-2
|
|
AU2021356684A1
(en)
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2022082109A1
(en)
|
2020-10-18 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
CA3195967A1
(en)
|
2020-10-28 |
2022-05-05 |
Xu Wang |
Vectorized anti-tnf-? antibodies for ocular indications
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
IL303239A
(en)
|
2020-12-01 |
2023-07-01 |
Univ Pennsylvania |
Compositions and their uses for the treatment of Engelmann syndrome
|
|
EP4263841A1
(en)
|
2020-12-16 |
2023-10-25 |
REGENXBIO Inc. |
Method of producing a recombinant adeno-associated virus particle
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
IL304006A
(en)
|
2020-12-29 |
2023-08-01 |
Akouos Inc |
Compositions and methods for treating hearing loss and/or vision loss associated with CLRN1
|
|
EP4277933A4
(en)
|
2021-01-14 |
2024-12-11 |
Senti Biosciences, Inc. |
SECRETABLE PAYLOAD REGULATION
|
|
JP2024503895A
(ja)
|
2021-01-21 |
2024-01-29 |
リジェネクスバイオ インコーポレイテッド |
組換えポリペプチド及びウイルスの生成の改善
|
|
WO2022165313A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US11926842B2
(en)
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
|
EP4291249A2
(en)
|
2021-02-10 |
2023-12-20 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
IL307633A
(en)
|
2021-04-12 |
2023-12-01 |
Univ Pennsylvania |
Useful preparations in the treatment of spinal muscular atrophy (SBMA)
|
|
CA3216004A1
(en)
|
2021-04-23 |
2022-10-27 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
US20240181084A1
(en)
|
2021-04-23 |
2024-06-06 |
University Of Rochester |
Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas Fusion Protein and Methods of Treatment
|
|
JP2024517143A
(ja)
|
2021-04-26 |
2024-04-19 |
リジェネックスバイオ インコーポレイテッド |
ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
AU2022299552A1
(en)
|
2021-06-25 |
2024-01-04 |
Oxford Biomedica (Us) Llc |
Adeno-associated virus packaging systems
|
|
US20240316102A1
(en)
|
2021-07-01 |
2024-09-26 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
US20240409955A1
(en)
|
2021-07-19 |
2024-12-12 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
US20250019721A1
(en)
|
2021-08-11 |
2025-01-16 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating a muscular dystrophy
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
JP2024535677A
(ja)
|
2021-08-11 |
2024-10-02 |
サナ バイオテクノロジー，インコーポレイテッド |
即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
|
|
US20240358761A1
(en)
|
2021-08-11 |
2024-10-31 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
US20230090654A1
(en)
|
2021-08-24 |
2023-03-23 |
Homology Medicines, Inc. |
Adeno-associated virus formulations
|
|
AR126877A1
(es)
*
|
2021-08-25 |
2023-11-22 |
Canbridge Pharmaceuticals Inc |
PARTÍCULAS DE AAV QUE COMPRENDEN UNA PROTEÍNA DE LA CÁPSIDE HEPATOTRÓPICA Y a-GLUCOSIDASA ÁCIDA (GAA) Y SU USO PARA TRATAR LA ENFERMEDAD DE POMPE
|
|
KR20240107201A
(ko)
|
2021-08-31 |
2024-07-08 |
스카우트 바이오, 인코포레이티드 |
항원-결합 분자 및 이의 용도
|
|
JP2024537775A
(ja)
|
2021-09-30 |
2024-10-16 |
アコーオス インコーポレイテッド |
Ｋｃｎｑ４関連難聴を治療するための組成物及び方法
|
|
EP4409010A1
(en)
|
2021-10-02 |
2024-08-07 |
The Trustees of The University of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
CN118201947B
(zh)
*
|
2021-10-28 |
2025-03-21 |
上海天泽云泰生物医药有限公司 |
腺相关病毒衣壳
|
|
US20250025574A1
(en)
|
2021-10-28 |
2025-01-23 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2023077086A1
(en)
|
2021-10-29 |
2023-05-04 |
Homology Medicines, Inc. |
Methods and compositions for the purification of adeno-associated virus
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
EP4441232A2
(en)
|
2021-12-01 |
2024-10-09 |
Shape Therapeutics Inc. |
Functional aav capsids for intravitreal administration
|
|
EP4440696A1
(en)
|
2021-12-01 |
2024-10-09 |
Shape Therapeutics Inc. |
Functional aav capsids for systemic administration
|
|
US20240408157A1
(en)
|
2021-12-02 |
2024-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2023106256A1
(ja)
*
|
2021-12-06 |
2023-06-15 |
学校法人順天堂 |
改変型アデノ随伴ウイルスベクター
|
|
WO2023114897A2
(en)
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
|
CN119317718A
(zh)
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
CN119301262A
(zh)
|
2022-04-01 |
2025-01-10 |
武田药品工业株式会社 |
用于具有cns表现的疾病的基因疗法
|
|
US20260034243A1
(en)
|
2022-04-06 |
2026-02-05 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
EP4504797A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
US20260034246A1
(en)
|
2022-05-03 |
2026-02-05 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
JP2025525439A
(ja)
|
2022-06-30 |
2025-08-05 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
US20260055144A1
(en)
|
2022-08-24 |
2026-02-26 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
AU2023331251A1
(en)
|
2022-08-25 |
2025-02-27 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
|
IL319873A
(en)
|
2022-09-30 |
2025-05-01 |
Regenxbio Inc |
Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
|
|
CN115960177B
(zh)
*
|
2022-10-09 |
2023-07-07 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
EP4601710A2
(en)
|
2022-10-11 |
2025-08-20 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
CN116789739B
(zh)
*
|
2022-12-08 |
2024-01-26 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4680741A2
(en)
|
2023-03-15 |
2026-01-21 |
RegenxBio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
KR20260010739A
(ko)
|
2023-05-11 |
2026-01-21 |
유니버시티 하스피탈즈 클리블랜드 메디컬 센터 |
항불안 치료
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
EP4716541A2
(en)
|
2023-05-22 |
2026-04-01 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
IL326390A
(en)
|
2023-08-10 |
2026-04-01 |
Univ Pennsylvania |
Compositions and methods for treating spinal muscular atrophy
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
TW202548022A
(zh)
|
2024-03-03 |
2025-12-16 |
美商帕西奇生物公司 |
用於治療神經退化性病症之重組腺相關病毒
|
|
US20250276095A1
(en)
|
2024-03-04 |
2025-09-04 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
TW202548025A
(zh)
|
2024-04-08 |
2025-12-16 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
WO2026011009A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Compositions and methods for muscle disorders
|
|
WO2026011008A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Expression control by skeletal muscle-expressed mirnas
|
|
CN118460614B
(zh)
*
|
2024-07-05 |
2025-03-11 |
凌意(杭州)生物科技有限公司 |
一种腺相关病毒Cap蛋白的表达框
|
|
WO2026030242A1
(en)
|
2024-07-29 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
|
|
WO2026030244A1
(en)
|
2024-07-30 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
|
|
WO2026036118A1
(en)
|
2024-08-09 |
2026-02-12 |
Shape Therapeutics Inc. |
Engineered aav capsid polypeptides and methods of use
|
|
WO2026044087A1
(en)
|
2024-08-21 |
2026-02-26 |
Shape Therapeutics Inc. |
Increased cellular stability for aav production
|
|
WO2026050402A1
(en)
|
2024-08-29 |
2026-03-05 |
Kate Therapeutics, Inc. |
Liver de-targeted muscle tropic capsids
|
|
CN118754952B
(zh)
*
|
2024-09-06 |
2025-01-10 |
上海玮美基因科技有限责任公司 |
一种新型腺相关病毒及其应用
|
|
WO2026073032A1
(en)
|
2024-09-27 |
2026-04-02 |
Shape Therapeutics Inc. |
Constructs for improved aav production
|